Pursuant to regulation 32 of SEBI (Listing Obligation and Disclosure Requirements, 2015, read with SEBI Circular No. CIR/CFD/CMD1/162/2019 dated 24th December, 2019 regarding submission of Statement of Deviation or Variation from proceeds of Public issue/right issue/preferential issue, Qualifed Institutions Placement,(QIP) etc, we hereby confirm that the Company has not raised any further funds by means of Public issue, Rights issue, or preferential Issue, etc. Hence, the statement of Deviation(s) or Variation(s) is not being provided as it is not applicable to the Company
Non-Applicability Of Statement Of Deviation Or Variation Under Regulation 32 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
View original source (BSE India)Vivanza Biosciences Ltd. on 6ix
Earlier from Vivanza Biosciences
- Outcome Of The Board Meeting And Submission Of Un-Audited Financial Results For The Quarter And Nine Months Ended 31ST December 2025
- Vivanza Biosciences Ltd. Press Release Feb 05 2026
- Board Meeting Intimation for Consideration Of Financial Result For The Quarter And Nine Months Ended 31St December, 2025
- Vivanza Biosciences Ltd. Press Release Jan 02 2026
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Later from Vivanza Biosciences
- Announcement under Regulation 30 (LODR)-Newspaper Publication
- Vivanza Biosciences Ltd. Press Release Feb 13 2026
- Closure of Trading Window
- Vivanza Biosciences Ltd. Press Release Mar 23 2026
- Vivanza Biosciences Ltd. Press Release Apr 07 2026
Follow Vivanza Biosciences into a list and get an email when it puts out news.
Follow Vivanza Biosciences